LLY · News · 20261105N

Clinical Trial Results

ELI LILLY & Co · 2026-11-05 · Importance 34 · Surprise 42

At ACR Convergence 2026, Lilly will present Phase 3 TRIUMPH-1 and TRIUMPH-4 results showing retatrutide reduced knee pain and weight in adults with knee osteoarthritis and obesity. Some participants reported no knee pain at trial end. One-year Phase 3b TOGETHER-PsA data showed that Taltz (ixekizumab) plus Zepbound improved disease activity, patient-reported outcomes and metabolic outcomes versus Taltz alone in adults with psoriatic arthritis and obesity.

Key facts

• Under a clinical trial collaboration and supply agreement with Zenith Epigenetics, Lilly will supply Verzenio for a registration-enabling study of ZEN-3694 and Verzenio in NUT carcinoma; the study is expected to begin in early 2027. source
• Eli Lilly will present new clinical and real-world research at ACR Convergence 2026, taking place Nov. 6-11 in Orlando. source
• Phase 3 TRIUMPH-1 and TRIUMPH-4 results showed retatrutide reduced knee pain and weight in adults with knee osteoarthritis and obesity; some participants had no knee pain at trial end. source
• Phase 3b TOGETHER-PsA data showed positive disease activity, patient-reported and metabolic outcomes at one year for Taltz and Zepbound versus Taltz alone in adults with psoriatic arthritis and obesity. source